(MedPage Today) — CHICAGO — First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF V600E-mutated metastatic colorectal…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115807
Author :
Publish date : 2025-05-29 19:00:00
Copyright for syndicated content belongs to the linked Source.
